

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

	Financial		Non-financial		Non-personal	Date received at SIGN Executive	Action
	Specific	Non-Specific	Specific	Non-Specific			
<b>CHAIR</b>							
Naveed Sattar, Professor of Metabolic Medicine	<p>Consultancy on PCSK9 inhibitor, involvement as investigator in 2 trials and speaker at two meetings –</p> <ul style="list-style-type: none"> <li>AMGEN (consultancy once, two trials, one ongoing where local PI, two speaker engagements over last 3 year</li> </ul> <p>Consultancy on PCSK9 inhibitor, and Chair of meeting –</p> <ul style="list-style-type: none"> <li>SANOFI (one consultancy and one meeting)</li> </ul>	<p>Professor of Metabolic Medicine University of Glasgow - Clinical Academic – with clinical, teaching and research roles.</p> <p>UK CI for EXSCEL trial – once weekly Exenatide vs placebo RCT in high risk diabetes -</p> <ul style="list-style-type: none"> <li>Now Astra-Zeneca but before Astra-Zeneca and BMS (ongoing trial due to end 2018). University receives fees for my involvement.</li> </ul> <p>Local PI for CANTOS Canakinumab -</p> <ul style="list-style-type: none"> <li>Novartis</li> </ul>	<p>I was co-author on paper on Mendelian randomisation of alcohol genes and CVD outcomes and mortality which suggested alcohol may not be protective for CVD.</p>	None	None	3.11.16	Declare, agreed to not participate or comment in alcohol KQs and not discuss conclusions relating to PCSK9 inhibitors.

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

		<p>(ongoing; trial due to end around 2018).</p> <p>Steering committee for ENTRACTE (II-6 R in CVD prevention in RA) –</p> <ul style="list-style-type: none"><li>• Roche (ongoing trial due to end around 2018) - University receives fees for my involvement (antibody for RA treatment being tested for CVD safety as non-inferiority trial demanded by FDA).</li></ul> <p>Consultancy/talk on CETP inhibitor work, drug –</p> <ul style="list-style-type: none"><li>• Eli Lilly (twice but over 18 months ago).</li></ul> <p>Consultancy /talks /trial work on empagaflozin – (a diabetes drug) –</p> <ul style="list-style-type: none"><li>• Boehringer Ingelheim (2</li></ul>					
--	--	---	--	--	--	--	--

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

		<p>consultancies/ 1 talk / 2 ongoing trials) - Self and University of Glasgow will also be compensated for my time involved in trials.</p> <p>GLP-1RA liraglutide and semaglutide</p> <ul style="list-style-type: none"> <li>• Novo Nordisk (2 consultancies over last 12 months).</li> </ul>					
<b>GUIDELINE DEVELOPMENT GROUP MEMBER</b>							
Lesley Allan, Principal Clinical Psychologist	Principal Clinical Psychologist, NHS Greater Glasgow & Clyde, Acute Psychology Service, Clinical Health Psychology Dept, West Glasgow Ambulatory Care Hospital	None	None	None	None	14.11.16	No action required

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

Ann Auld, Pharmacist	Lead Pharmacist Prescribing Management, NHS Lanarkshire.  Consultant Pharmacist (Pharmacy Consultancy).	Advisory boards – • Janseen-Cilag, • AZ, • Tillots • Pharma, • Takeda, • Novartis, • Ipsen, • Leo Pharma.  Research project – Branding Science	None	Member of Diabetes UK  Member of National Kidney Federation	None	23.10.16	Declare and participate
Richard Forsyth, BHF Area Development Manager	Health Services Engagement Lead (Scotland), British Heart Foundation.	None	None	None	None	28.9.16	No action required
Jason Gill, Reader in Exercise Science	Reader in Exercise Science, University of Glasgow.  Speaking at educational events for healthcare professionals about effects of physical activity, diet and lifestyle on prevention and management of	None	None	Member of: American College of Sports Medicine, British Association of Sport and Exercise Science, Diabetes UK, HEART UK, Nutrition Society, Physiological Society	None	3.11.16	Declare and participate

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

	<p>cardio-metabolic diseases –</p> <ul style="list-style-type: none"> <li>• AstraZeneca (twice in 2016),</li> <li>• Janssen (once in 2016).</li> </ul>						
Douglas Hamilton, General Practitioner	<p>Occasional shifts worked as out of hours General Practitioner – NHS GG &amp; C.</p> <p>Property owning partner in GP surgery. Northcote Surgery, General Medical Practice.</p>	None	None	None	None	4.11.16	No action required
Catherine Hankey, Senior Lecturer in Human Nutrition	<p>Senior Lecturer, University of Glasgow.</p> <p>Completed a term of office at the Association for the study of obesity (a charity not funded by industry).</p>	None	None	None	None	7.11.16	No action required

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

John Hitchon, Lay Representative	Retired 1991.  229 shares in AZ.  819 shares in GSK.  3,317 shares in Smith & Nephew.	None	None	None	None	3.10.16	Declare and participate
Chris Macnamee, Lay Representative	None	None	None	None	None	18.1.17	No action required
Jill Morrison, Professor of General Practice and Dean of Learning and Teaching	Dean for Learning and Teaching and Professor of General Practice, University of Glasgow. Academic general practice and college management.	None	None	None	None	28.9.16	No action required
Brian O Suilleabhain, Consultant in Public Health Medicine	Consultant in Public Health Medicine, NHS Ayrshire & Arran.	None	None	None	None	27.9.16	No action required

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

David Preiss, Clinical Senior Lecturer and Honorary Consultant in Metabolic Medicine	MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford – Academic employment.	None	None	None	None	29.9.16	No action required
Graeme Tait, Consultant Cardiologist	Consultant cardiologist, NHS Dumfries & Galloway  Private healthcare – Dr G.W. Tait	None	None	None	None	3.11.16	No action required
John Webster, Consultant Physician	Consultant Physician (retired 30/6/2016). Now Honorary Consultant, Clinical Pharmacology, NHS Grampian.	None	None	None	Sponsor: Univ. of Dundee (Main funding source: Menarini)  Participation in FAST trial (allopurinol vs febuxostat in gout – cardiovascular outcomes).	3.11.16	Declare and participate. Agreed to not participate in discussions relating to PCSK9 inhibitors.

## REGISTER OF INTERESTS

SIGN guideline: Risk estimation and the prevention of cardiovascular disease

Published: 26 July 2017

25 July 2017

					<p>Sponsor: University of London (Main funding source: Amgen)</p> <p>Participation in FOURIER trial (PCSK9i - evolocumab added to statin in secondary prevention of cardiovascular disease)</p> <p>Sponsor: University of Oxford (Main funding source: MSD)</p> <p>Participation in REVEAL trial (anencetrapib added to statin in secondary prevention of cardiovascular disease)</p> <p>All funds for these trials processed via R&amp;D Dept, NHS Grampian.</p>		
--	--	--	--	--	---	--	--